BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension

Reuters10-30

Oct 30 (Reuters) - Mineralys Therapeutics Inc :

* MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION

* MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN TRIAL EXPECTED MID FIRST HALF OF 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479057207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 21:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479057207","market":"us","top_or_hot":-1,"title":"BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension","media":"Reuters","content":"<html><body><p>Oct 30 (Reuters) - Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION</p><p>   * MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN TRIAL EXPECTED MID FIRST HALF OF 2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Mineralys Therapeutics Completes Enrollment Ahead Of Schedule In Launch-HTN, The Second Pivotal Trial Of Lorundrostat For The Treatment Of Hypertension\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 21:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 30 (Reuters) - Mineralys Therapeutics Inc   :   * MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2479057207","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479057207","pubTimestamp":1730293916,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Oct 30  - Mineralys Therapeutics Inc   :   * MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION   * MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN TRIAL EXPECTED MID FIRST HALF OF 2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4139":"生物科技","MLYS":"Mineralys Therapeutics, Inc."},"translate_title":"简介-Mineralys Therapeutics提前完成Launch-HTN的招募，这是Lorundrostat治疗高血压的第二项关键试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MLYS":0.9},"content_text":"Oct 30 (Reuters) - Mineralys Therapeutics Inc   :   * MINERALYS THERAPEUTICS COMPLETES ENROLLMENT AHEAD OF SCHEDULE IN LAUNCH-HTN, THE SECOND PIVOTAL TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION   * MINERALYS THERAPEUTICS INC - TOPLINE DATA FROM LAUNCH-HTN TRIAL EXPECTED MID FIRST HALF OF 2025Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479057207"}